Performance of a Patient Reported Outcomes Measurement Information System (PROMIS) Short Form in Older Adults with Chronic Musculoskeletal Pain

Deyo, Richard A.; Ramsey, Katrina; Buckley, David I; Michaels, LeAnn; Kobus, Amy; Eckstrom, Elizabeth; Forro, Vanessa A.; Morris, Cynthia D.

doi:10.1093/pm/pnv046

Cited by 92 publications

(115 citation statements)

References 48 publications

Supporting

Mentioning

100

Contrasting

Order By: Relevance

“…Responsiveness of PROMIS-PI was supported in a few studies. 30,7,2 These studies revealed significant changes in PROMIS-PI scores post-treatment 2; 29; 30 or expected relationships between changes in PROMIS-PI and anchor measures. 7; 21 In other studies, however, the responsiveness of PROMIS-PI was not well supported.…”

Section: Introductionmentioning

confidence: 80%

Comparative Responsiveness of the PROMIS Pain Interference Short Forms With Legacy Pain Measures: Results From Three Randomized Clinical Trials

Chen

Kroenke

Stump

et al. 2019

The Journal of Pain

View full text Add to dashboard Cite

 The PROMIS Pain Interference short forms are responsive to change. Their responsiveness are comparable to legacy pain measures. Responsiveness may vary based on the sample and the direction of change. ABSTRACTThe PROMIS Pain Interference (PROMIS-PI) scales are reliable and publicly accessible; however, little is known about how responsive they are to detect change in clinical trials and how their responsiveness compares to legacy measures. The study purpose was to evaluate responsiveness for the PROMIS-PI scales and to compare their responsiveness with legacy pain measures. We used data from three clinical trials totaling 759 participants. The clinical trials included patients with chronic low back pain (n= 261), chronic back or osteoarthritis pain (n ACCEPTED MANUSCRIPT A C C E P T E D M A N U S C R I P T 2 = 240), and a history of stroke (n= 258). At both baseline and follow-up, participants completed PROMIS-PI scales and legacy pain measures (Brief Pain Inventory Interference scale, Pain/Enjoyment/General Activity (PEG) scale, SF-36 Bodily Pain scale, and Roland-Morris Disability Questionnaire). We measured global ratings of pain change, both prospectively and retrospectively, as anchors to identify patients as improved, unchanged, or worsened. Responsiveness was assessed with standardized response means, statistical tests comparing change groups, and area-under-curve analysis. The PROMIS-PI scales had largely comparable responsiveness with the Brief Pain Inventory Interference scale and PEG. The four PROMIS-PI short forms had comparable responsiveness. For all pain questionnaires, responsiveness varied based on the study population and whether pain improved or worsened. Perspective: This paper presents (1) how responsive the PROMIS Pain Interference scales were to detect change over time in the context of three clinical trials and (2) how their responsiveness compared to legacy pain measures. The findings can help researchers and clinicians choose between different patient-reported pain outcome measures.

show abstract

Section: Introductionmentioning

confidence: 80%

Comparative Responsiveness of the PROMIS Pain Interference Short Forms With Legacy Pain Measures: Results From Three Randomized Clinical Trials

Chen

Kroenke

Stump

et al. 2019

The Journal of Pain

View full text Add to dashboard Cite

show abstract

“…The FOP registry has utilized PROMIS, a system developed by the National Institutes of Health that provides a standardized, flexible, and reliable test bank of patient‐reported outcomes for clinical research . Having incorporated comprehensive domains for pain assessment and patient health, PROMIS has been used in many studies to evaluate patients’ pain‐related experience (eg, intensity, interference, quality, and impact), associated physical or mental conditions, and social functions across multiple chronic conditions . In order to expand upon findings emanating from the current study, future work may employ the same PROMIS‐based questionnaires in trials evaluating disease‐modifying treatments or therapies aimed at treating FOP symptomology.…”

Section: Discussionmentioning

confidence: 99%

Longitudinal Evaluation of Pain, Flare‐Up, and Emotional Health in Fibrodysplasia Ossificans Progressiva: Analyses of the International FOP Registry

et al. 2019

View full text Add to dashboard Cite

Fibrodysplasia ossificans progressiva (FOP) is an ultra‐rare, inherited, connective tissue disease with ∼800 documented cases worldwide. The principal pathological feature of FOP is the transition of skeletal muscle, tendons, ligaments, and fascia into cartilage and bone. This heterotopic ossification (HO) is often preceded by painful soft tissue swellings or flare‐ups that may last several months. For many individuals, experiencing a flare‐up may represent a worsening of their condition and contribute to feelings of anxiety or suppressed affect, both of which are well‐recognized to exacerbate pain perception. To date, much remains unknown regarding the dynamics of pain and emotional health in FOP during flare‐up and also quiescent, non–flare‐up disease phases. In order to elucidate the occurrence and effect of pain in FOP, this study analyzed Patient‐Reported Outcomes Measurement Information System–based questionnaires completed by 99 patients participating in the international FOP Registry over a 30‐month period. We observed that although moderate to severe pain (≥4, 0 to 10 pain scale) was commonly associated with flare‐ups (56% to 67%), surprisingly, 30% to 55% of patients experienced similar pain levels during non–flare‐up states. In those patients reporting pain levels of ≥4, 45% to 74% of patients report experiencing anxiety, depression, or irritability, with 36% to 48% reporting emotional problems during no to mild pain states. Furthermore, independent of the flare‐up status, the severity of pain in FOP patients was found to be significantly anti‐correlated with emotional health, physical health, and overall quality‐of‐life. These findings strongly suggest the need for an improved understanding of pain and emotional health in FOP during flare‐up and quiescent periods. © 2019 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.

show abstract

“…24 Such scales have been validated in several populations, including in patients suffering from chronic musculoskeletal pain. 27 A combination of low back pain intensity in the past 7 days, physical function and pain interference PROMIS scores allows for the computation of an Impact Score, which has been validated among patients with chronic musculoskeletal pain. [14][15][16][17][18][19][20][21][22]27 Cross-cultural adaptation of the minimum data set…”

Section: Methodsmentioning

confidence: 99%

“…For example, further validation studies should be conducted to assess the full range of psychometric properties of the Impact Score [14][15][16][17][18][19][20][21][22]27 using the new French-Canadian version of the questionnaire.…”

Section: Limitationsmentioning

confidence: 99%

The Canadian minimum dataset for chronic low back pain research: a cross-cultural adaptation of the National Institutes of Health Task Force Research Standards

et al. 2017

View full text Add to dashboard Cite

Performance of a Patient Reported Outcomes Measurement Information System (PROMIS) Short Form in Older Adults with Chronic Musculoskeletal Pain

Cited by 92 publications

References 48 publications

Comparative Responsiveness of the PROMIS Pain Interference Short Forms With Legacy Pain Measures: Results From Three Randomized Clinical Trials

Comparative Responsiveness of the PROMIS Pain Interference Short Forms With Legacy Pain Measures: Results From Three Randomized Clinical Trials

Longitudinal Evaluation of Pain, Flare‐Up, and Emotional Health in Fibrodysplasia Ossificans Progressiva: Analyses of the International FOP Registry

The Canadian minimum dataset for chronic low back pain research: a cross-cultural adaptation of the National Institutes of Health Task Force Research Standards

Contact Info

Product

Resources

About